Yarrow Bioscience Inc
YARW
NASDAQ·Healthcare·Biotechnology·Mkt cap $207.2M
$23.60
▲ +4.80%
P/E
—
Mkt Cap
$207.2M
52-Wk Range
$16.00–$46.95
52-Week Range
$16.00 - $46.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 23.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Value
Valuation data unavailable
Momentum
Falling
-33.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying YARW right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$2.14 vs -$11.00 consensus (+80.5% surprise). Revenue of $97.0K vs $200.0K expected (-51.5%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+80.5%
Revenue trend · last 8Q
—
—
—
—
+40%
+55%
-57%
+41%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$121.0K
$84.0K
$202.0K
$69.0K
$169.0K
$130.0K
$86.0K
$97.0K
Margins · last 8Q
Gross
0.0%
Profit
-3100.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How YARW stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.